CERE

AbbVie completes acquisition of Cerevel Therapeutics

PremiumThe Fly

4M ago

CERE Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

4M ago

AbbVie expects Cerevel Therapeutics transaction to close ‘soon’

PremiumThe Fly

4M ago

Cerevel Therapeutics weakness attributed to CTFN report

PremiumThe Fly

5M ago

PremiumThe FlySoros buys Okta, cuts Amazon in Q1

6M ago

AER

CRH

CERE Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pre-Earnings

CERE Earnings Report this Week: Is It a Buy, Ahead of Earnings?

7M ago

The Fly

Cerevel Therapeutics’ tavapadon meets Phase 3 primary endpoint in Parkinson’s

7M ago

CERE Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

8M ago

Cerevel Therapeutics Advances in Merger Amid FTC Review

PremiumCompany Announcements

9M ago

Cerevel Therapeutics price target raised to $45 from $25 at Mizuho

PremiumThe Fly

9M ago

Neurocrine price target raised to $106 from $100 at Piper Sandler

PremiumThe Fly

10M ago

KRTX

PremiumThe FlyNeumora Therapeutics appoints Panandiker as Chief Commercial Officer

10M ago

NMRA

The Fly

Cerevel Therapeutics price target raised to $45 from $25 at JPMorgan

11M ago

Karuna downgraded, Arm target raised: Wall Street’s top analyst calls

Reviva may be most undervalued in neurology, says H.C. Wainwright

The Fly

Karuna downgraded, Arm target raised: Wall Street’s top analyst calls

11M ago

ARM

BMY

PremiumThe Fly

11M ago

Cerevel Therapeutics price target raised to $45 from $30 at Wells Fargo

KRTX

PremiumThe Fly

11M ago

Cerevel Therapeutics downgraded to Hold from Buy at Jefferies

PremiumThe Fly

11M ago

Cerevel Therapeutics just downgraded at Stifel, here’s why

PremiumThe Fly

11M ago

PremiumThe FlyCerevel Therapeutics downgraded to Hold from Buy at Stifel

11M ago

The biopharma stocks to own in 2024, according to Morgan Stanley

The Fly

The biopharma stocks to own in 2024, according to Morgan Stanley

12M ago

BMY

JNJ